AzTrials
AzTrials

StrokeVASSTIINCT01996137

VASSTII: An Exploratory Clinical Study on a VASST IITreadmill System for Post Stroke Gait Rehabilitation.

A study testing VASST II treadmill in people with Stroke and Hemiplegic Gait, run by Tan Tock Seng Hospital at 1 site in Singapore.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

An exploratory clinical study on a Variable Speed and Sensing Treadmill system(VASST) for hemiparetic gait rehabilitation after stroke. Building upon the positive results of VASST I conducted in 2012, VASST II will be an open label pilot trial of 11 subjects screened for eligibility by TTSH medical and rehabilitation… Read more about this study

Who is it for?
Ages 21 to 80 years
Conditions the study is for
Stroke, Hemiplegic Gait
What is being tested?
VASST II treadmill
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
11 participants
Where
1 siteSingapore
Study dates
24 Sep 2018to 15 Jun 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 21 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • First ever stroke (ischaemic or haemorrhagic) confirmed on CT or MR imaging
  • Aged 21 - 80 years
  • Stroke duration of > 3 months - 24 months (subacute -chronic stroke)
  • Able to walk overground at a self-selected speed of >0.2m/s with or without walking aids or lower limb orthoses for at least 150 meters with at most minimal aid or supervision.
  • Functional ambulation category (FAC >/= 2) (subject needs at most minimal assistance to walk)

Who cannot join

  • Cardiovascular conditions such as uncontrolled hypertension/hypotension, angina pectoris, recent myocardial infarction, congestive cardiac failure, known echocardiographic ejection fraction < 40%, chronic arrhythmias (e.g. atrial fibrillation), pacemaker, uncontrolled Diabetes Mellitus.; within 3 months of study screening
  • Terminal illness such as advanced malignancy, end stage renal failure, neurodegenerative diseases with life expectancy of < 6 months.
  • Aphasia (inability to obey 2 step commands), cognitive impairment, untreated depression or psychiatric disorder.
  • Severe hearing or visual impairment despite aids.
  • Active lower limb arthritis, lower limb or joint pain (Visual Analogue Scale) >5/10, fixed orthopaedic deformities and peripheral vascular disease of the lower limb which could be worsened by treadmill training.
  • Moderate to severe lower limb spasticity or spasms (Modified Ashworth Scale >2)
Show all 9Show fewer
  • Active trunk skin conditions, known abdominal aortic aneurysm, anticoagulation with warfarin precluding safe fit of unweighting gait harness.
  • Body weight > 130kg.
  • Pregnancy.

Trial locations and contacts

1 site in 1 country.

Singapore1 site
  • Tan Tock Seng Hospital CART 5B

    Singapore, 308433

Other trials in Singapore

About this study

Official title: An Exploratory Clinical Study on a Variable Speed and Sensing Treadmill (VASST II) System for Hemiparetic Gait Rehabilitation After Stroke

An exploratory clinical study on a Variable Speed and Sensing Treadmill system(VASST) for hemiparetic gait rehabilitation after stroke.

Building upon the positive results of VASST I conducted in 2012, VASST II will be an open label pilot trial of 11 subjects screened for eligibility by TTSH medical and rehabilitation team Study hypotheses : Training on VASST may result in a gain of +40% - 50% for distance walked and +10-20% of gait speed compared to baseline and response rate of 85% and serious adverse event rate of <10%.

Read the detailed description

A recent collaboration with Ngee Ann Polytechnic's team from the Biomedical Engineering Centre, Electronic \& Computer Engineering Division, School Of Engineering Singapore yielded the VASST I; an innovative product, the result of co development between NP and TTSH rehabilitation centre's CART (Centre for Advanced Rehabilitation Therapeutics) was supported by a competitive grant. (EMBC paper ref, SIRF)

VASST I incorporates the following features which enhance manual treadmill training:

  1. Sensing mechanisms to track user's self-activated actions during exercise.
  2. Automated speed-control to adapt to a user's gait speed and pattern.
  3. Safety sensing to slow down the treadmill when the user is unable to sustain the treadmill speed in order to avert a potential fall.
  4. Overhead safety harness without body weight support for reduction of fall risk.
  5. Software tools to collect vital clinical data regarding ambulatory gait speed, distance and time walked during treatment.

A recently completed proof of concept trial in June 2013 yielded encouraging results in 10 chronic poststroke hemiplegic subjects. All subjects completed the trial without any adverse events. The clinical team was able to smoothly test-bed VASST in 10 subjects with good subjective feedback. Following 12 hour - long supervised training sessions over 4 weeks, there were significant gains from baseline for measures of gait quantity (+30.1%) and gait speed (+8.7%). These gains were maintained for up to 4 weeks after training ceased. The response rate was 80% and positive feedback was obtained in 80% of subjects. Objective measurements were obtained using independent kinematic gait analysis using the Gaitrite system.

With these encouraging results, the combined TTSH and Ngee Ann medical and bioengineering teams have brought the co-development to a deeper level, leading to VASST II which is conceptualized as a pre-commercialisation prototype.

Additional technological improvements include:

  1. Automated unweighting subsystem of up to 20% body weight support to benefit more severely impaired subjects in terms of reduction of physical fatigue during ambulation and to reduce destabilization or fall risk during higher gait training speeds.
  2. Hand grip sensors to intelligently guide progression of training speeds
  3. Instrumentation subsystem including sensors to record spatial and temporal gait measurements during gait training such as step and stride length, gait speed / distance walked. An anticipated sensor accuracy of +/- 1.27 cm similar to the Gaitrite system in measuring step length may potentially allow ambulatory gait monitoring, obviating the need for additional independent post-training analysis using a gait measurement instrument such as Gaitrite.
  4. Real-time feedback subsystem with graphical LCD display which is interactive and varied in order reduce boredom and motivate users.
  5. Wireless data transfer subsystem for data storage and analysis to a laptop computer for the treating therapist.

Research objectives

  1. To provide clinical inputs into VASST II via systematic hazard analyses, in order to arrive at a prototype which may attract commercial interest for licensing and manufacture and eventual deployment to ambulatory rehabilitation clinics in hospitals and day rehabilitation centres.
  2. To conduct of a pilot clinical trial using VASST II for 11 subacute to chronic (>3 months) hemiplegic stroke patients in an ambulatory setting.
  3. To obtain pre and post outcomes using standardized clinical scales and objective measurements of gait parameters during exercise. (gait speed, quantity, cadence, step length)
  4. To obtain subjective feedback with regards to their experience after using VASST II from research subjects and therapists.
Being tested
VASST II treadmill
Keywords
Stroke, Treadmill, Gait Speed
Medical subject headings
Stroke, Gait Disorders, Neurologic

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • VASST II treadmillDevice

    Also called Variable Automated Speed and Sensing Treadmill version II

    Supervised treadmill training under physiotherapist

Study groups in NCT01996137
Study groupRoleWhat they receive
VASST IIExperimentalStroke patients selected to undergo VASST II treadmill training for 60 minutes x15 sessions over 5 weeks Outcomes at week 0.3 6.12.24
Receives: Device: VASST II treadmill

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. 6 minute walk test

    distance (metres) walked in 6 minutes

    Measured: 6 weeks

Secondary outcomes (2)
  1. Gait speed

    seconds taken to walk 10 metre

    Measured: 6 weeks

  2. Functional ambulation category FAC

    Walking independence description

    Measured: 6 weeks

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted27 Nov 2013 (estimated)
  2. Study start24 Sep 2018
  3. Primary completion15 Jun 2019
  4. Study completion15 Jun 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Model description
1 hour of VASST II training, total 15 sessions over 5 weeks continuously
Masking
None (open label)
Enrolment
11 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT01996137
Sponsor's protocol ID
NHGDSRB_D_2013/01042
Acronym
VASSTII
Status last verified
Sep 2019
First submitted
21 Nov 2013
Last updated
13 Sep 2019
Results posted
No
Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing VASST II treadmill in people with Stroke and Hemiplegic Gait, run by Tan Tock Seng Hospital at 1 site in Singapore.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 5 inclusion and 9 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 13 Sep 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Singapore. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

6 minute walk test (time frame: 6 weeks). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 13 Sep 2019.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
VASSTII Clinical Trial NCT01996137 | AzTrials